MARKET

CYTK

CYTK

Cytokinetics Inc
NASDAQ
74.81
+0.25
+0.34%
After Hours: 74.79 -0.02 -0.03% 19:52 05/12 EDT
OPEN
74.68
PREV CLOSE
74.56
HIGH
75.23
LOW
73.13
VOLUME
2.42M
TURNOVER
--
52 WEEK HIGH
80.20
52 WEEK LOW
29.31
MARKET CAP
10.03B
P/E (TTM)
-10.9330
1D
5D
1M
3M
1Y
5Y
1D
Cytokinetics Is Maintained at Overweight by JP Morgan
Dow Jones · 11h ago
Cytokinetics Price Target Raised to $97.00/Share From $92.00 by JP Morgan
Dow Jones · 11h ago
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $97
Benzinga · 11h ago
Cytokinetics price target raised to $97 from $92 at JPMorgan
TipRanks · 14h ago
Why Cytokinetics (CYTK) Is Up 12.9% After Strong Phase 3 MYQORZO HCM Data And Expanded Reach
Simply Wall St · 14h ago
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
Reuters · 19h ago
CYTOKINETICS INC <CYTK.O>: JP MORGAN RAISES TARGET PRICE TO $97 FROM $92
Reuters · 23h ago
Cytokinetics Presents New Data From Its SEQUOIA-HCM Pivotal Phase 3 Clinical Study Of Aficamten In Participants With oHCM; MAPLE-HCM At European Society Of Cardiology Heart Failure 2026 Congress
Benzinga · 1d ago
More
About CYTK
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

Webull offers Cytokinetics, Inc. stock information, including NASDAQ: CYTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYTK stock methods without spending real money on the virtual paper trading platform.